A medical geneticist is reviewing the charts of several adult and pediatric patients with complex genetic presentations. To finalize their diagnostic formulations and targeted management plans, match each patient's clinical presentation and preliminary genetic findings to the precise underlying molecular or targeted therapeutic mechanism.
- An adult female with endometrial adenocarcinoma demonstrates isolated loss of MSH2 and MSH6 on immunohistochemistry, but genomic sequencing reveals no pathogenic sequence variants within the coding regions of either mismatch repair gene.Hypermethylation of a mismatch repair gene promoter secondary to a deletion in the adjacent upstream EPCAM gene.
- A male patient in his mid-thirties develops progressive gait ataxia. His father developed similar symptoms at age 62, reflecting a phenomenon driven by meiotic instability of a specific pathogenic allele.Expansion bias of a pathogenic trinucleotide repeat sequence that occurs specifically during spermatogenesis.
- An infant with profound hypotonia and areflexia secondary to a homozygous SMN1 deletion is successfully stabilized using an intrathecally administered molecular therapy.Therapeutic alteration of alternative pre-mRNA splicing to increase the translation of a functional paralogous gene.
- An asymptomatic couple seeking preconception counseling is found to carry two completely different pathogenic variants in the CFTR gene, raising questions about predicting their offspring's specific pulmonary and pancreatic phenotype.Compound heterozygosity dictating the overall residual protein function and subsequent clinical severity.
- A young adult male experiences subacute, painless bilateral central vision loss. His maternal uncle suffered a similar fate, while his mother only has mild, subclinical color vision abnormalities.Stochastic distribution of mutated extranuclear genomes during cell division dictating phenotypic penetrance.
Answer
The correct matches require linking the clinical phenotype and test results to their advanced molecular mechanisms: MSH2 loss without coding mutation matches EPCAM-induced hypermethylation; progressive ataxia with anticipation matches expansion bias during spermatogenesis; hypotonia treated with targeted therapy matches alteration of SMN2 alternative splicing; inheritance of two distinct CFTR mutations matches compound heterozygosity; and maternally inherited vision loss with variable severity matches stochastic distribution of extranuclear genomes (heteroplasmy).
Each correct pairing directly connects a complex clinical presentation to a high-yield, advanced molecular mechanism. Recognizing that EPCAM deletions epigenetically silence MSH2, that CAG repeats undergo massive expansion during spermatogenesis, that nusinersen alters SMN2 splicing, that two different variants in one gene constitute compound heterozygosity, and that mitochondrial disease severity relies on heteroplasmy are all essential competencies for diagnostic evaluation and patient counseling at the independent practitioner level.
Step-by-Step Solution
Key Concept
Advanced molecular diagnostics and targeted pharmacogenomics often rely on identifying mechanisms beyond simple Mendelian inheritance, including epigenetic silencing (EPCAM/MSH2), expansion bias during specific gametogenesis (CAG repeats in spermatogenesis), alternative splicing modulation (SMA therapy), compound heterozygosity, and mitochondrial heteroplasmy.